Priority Review

1 / 1
Novartis
Priority Review

Novartis Lung Cancer Drug Granted Priority FDA Review

Novartis

PR-M02-20-NI-010Feb 11, 2020
AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi
M&A

AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi

Nice Insight

PR-M08-19-NI-083-2192Aug 28, 2019
Melinta’s Antibiotic Baxdela Gets Priority Review from FDA for CAPB
Priority Review

Melinta’s Antibiotic Baxdela Gets Priority Review from FDA for CAPB

Pharma's Almanac

PAO-M07-19-NI-005Jul 01, 2019
Amarin
NDA

U.S. FDA Grants Priority Review For Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication

Amarin

PR-M05-19-NI-080May 29, 2019
Novartis
FDA Acceptance

Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD

Novartis

PR-M04-19-NI-053Apr 17, 2019
FDA Grants Priority Review to Dupixent for Treatment of Adults with Severe Chronic Rhinosinusitis
Priority Review

FDA Grants Priority Review to Dupixent for Treatment of Adults with Severe Chronic Rhinosinusitis

Emilie Branch

Pharma's Almanac

PAO-M03-19-NI-017Mar 12, 2019
FDA Gives Novartis Gene Replacement Therapy Application Priority Review
FDA

FDA Gives Novartis Gene Replacement Therapy Application Priority Review

Emilie Branch

Pharma's Almanac

PAO-M12-18-NI-003Dec 05, 2018
Bayer
Drug Application

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

Bayer

PR-M05-18-NI-115May 31, 2018
China FDA Publishes Guidance for Priority Review
CFDA

China FDA Publishes Guidance for Priority Review

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M01-18-NI-013Jan 09, 2018
1 / 1